亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1.

医学 耐受性 细胞因子释放综合征 多发性骨髓瘤 内科学 不利影响 CD3型 肿瘤科 胃肠病学 免疫疗法 免疫学 癌症 抗原 CD8型 嵌合抗原受体
作者
Monique C. Minnema,Amrita Krishnan,Jesús G. Berdeja,Albert Oriol Rocafiguera,Niels W.C.J. van de Donk,Paula Rodríguez‐Otero,Daniel Morillo,María‐Victoria Mateos,Luciano J. Costa,Jo Caers,Deeksha Vishwamitra,Joanne Ma,Shiyi Yang,Brandi Hilder,Jaszianne Tolbert,Jenna D. Goldberg,Ajai Chari
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 8015-8015 被引量:16
标识
DOI:10.1200/jco.2022.40.16_suppl.8015
摘要

8015 Background: G protein-coupled receptor family C group 5 member D (GPRC5D), which has limited expression in normal human tissue but is highly expressed on malignant plasma cells, is a promising target for multiple myeloma (MM) immunotherapy. Talquetamab (JNJ-64407564) is a first-in-class, bispecific IgG4 antibody that binds to both GPRC5D and CD3 receptors, mediating T-cell–activated lysis of GPRC5D+ MM cells. Here we report updated results with additional patients (pts) and longer follow-up from MonumenTAL-1, a phase 1 trial of talquetamab in RRMM (NCT03399799). Methods: Eligible pts had RRMM or were intolerant to standard therapies; prior B-cell maturation antigen-directed therapies were permitted. The primary objectives were to identify the recommended phase 2 doses (RP2Ds) (part 1) and assess talquetamab safety and tolerability at the RP2Ds (part 2). Collective safety, efficacy, PK, and PD data supported 2 RP2Ds for talquetamab: 405 μg/kg SC QW (n = 30) and 800 μg/kg SC Q2W (n = 44). Step-up dosing was used to mitigate against severe cytokine release syndrome (CRS); required premedications were limited to step-up doses and the first full dose of talquetamab. Adverse events (AEs) were graded by CTCAE v4.03 with CRS events graded per Lee et al 2014 criteria. Investigators assessed responses per International Myeloma Working Group criteria. Results: As of Jan 17, 2022, pts in the 405 μg/kg/800 μg/kg groups, respectively, received a median of 6 /5 prior lines of therapy, 100%/98% were triple-class (TC) exposed, 77%/75% were TC refractory. Median follow-up (range) was 11.7 (1.0–21.2)/4.2 (0.7–13.7) months. Most AEs were grade 1 or 2. The most common AEs were cytopenias and CRS. Cytopenias (including neutropenia [67%/36%; grade 3/4: 53%/23%]) were reversible, mostly confined to step-up and cycle 1–2 doses, and generally resolved within 1 week. Infections occurred in 47%/34% (grade 3/4: 7%/9%) of pts. CRS (77%/80%; grade 3: 3%/0%) mostly occurred during step-up dosing. Skin-related and nail disorder AEs occurred in 83%/75% of pts (most commonly skin exfoliation: 37%/39% [all grade 1 and 2]). Dysgeusia (63%/57%) was generally mild and managed with dose adjustments. The overall response rates in response-evaluable pts were 70% (21/30 pts)/64% (28/44 pts); very good partial response or better rate: 57%/52%; median time to first confirmed response (range): 0.9 (0.2–3.8)/1.2 (0.3–6.8) months. Median duration of response will be reported. No pts died due to drug-related AEs. The PK and PD profiles of both RP2Ds appear comparable. Conclusions: These data show that both RP2Ds of talquetamab have comparable safety, efficacy, and pharmacokinetic profiles and confirm talquetamab as a novel, first-in-class therapy with highly promising efficacy in a heavily pretreated RRMM pt population. Clinical trial information: NCT03399799.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆的应助被吐司采纳,获得10
1秒前
海洋球发布了新的文献求助10
2秒前
dolabmu完成签到 ,获得积分10
4秒前
魔幻雅柔完成签到,获得积分10
5秒前
月亮打烊完成签到 ,获得积分10
8秒前
文静楷瑞完成签到,获得积分10
11秒前
fx完成签到 ,获得积分10
13秒前
13秒前
fantasy的应助被十三采纳,获得10
14秒前
深情安青的应助被outlast采纳,获得10
19秒前
十三完成签到,获得积分10
20秒前
21秒前
25秒前
拼搏问薇完成签到 ,获得积分10
26秒前
27秒前
Abcqqq完成签到 ,获得积分10
27秒前
海洋球完成签到,获得积分10
29秒前
ll完成签到,获得积分20
29秒前
小蘑菇的应助被xx2026采纳,获得10
30秒前
31秒前
kxz完成签到 ,获得积分10
31秒前
32秒前
gale发布了新的文献求助10
35秒前
红墨发布了新的文献求助30
36秒前
38秒前
怕黑的驳完成签到,获得积分10
39秒前
41秒前
42秒前
43秒前
44秒前
吐司发布了新的文献求助10
45秒前
冷静新烟完成签到,获得积分10
45秒前
gale完成签到,获得积分10
48秒前
53秒前
53秒前
TIDUS完成签到,获得积分10
55秒前
独特的念柏完成签到,获得积分10
59秒前
sadascaqwqw发布了新的文献求助10
59秒前
36hours完成签到,获得积分10
1分钟前
田様的应助被冷静新烟采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195004
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872554
捐赠科研通 7794720
什么是DOI,文献DOI怎么找? 3437836
关于科研通互助平台的介绍 2561159
邀请新用户注册赠送积分活动 2484541